

Changes in the composition of the Intrasense Board of Directors

Montpellier, France, February 9, 2026, 5:45 pm. [Intrasense](#) (ISIN : FR0011179886 – Mnémo : ALINS), [French expert in AI-enhanced medical imaging solutions that facilitate diagnosis, decision-making](#), announces changes to the composition of its Board of Directors.

The Company's Board of Directors has acknowledged the resignation of Mr. Jérôme Estampes from his position as director of the Company, effective November 14, 2025. At its meeting on November 17, 2025, the Board of Directors appointed Luke Poloniecki as director, effective as of that meeting. Mr. Luke Poloniecki has been appointed until 2029.

The Board of Directors of Intrasense would like to warmly thank Mr. Jérôme Estampes for his dedicated contribution to the work of the Board. It welcomes Mr. Luke Poloniecki and looks forward to working with him in the future.



Luke Poloniecki has over 20 years of strategy and M&A experience focused on identifying and harnessing healthcare innovation, across pharmaceuticals, medical technology, and artificial intelligence.

He spent ten years in Business Development and Licensing currently at Guerbet, and previously at BTG / Boston Scientific; underpinned by over a decade in investment banking, notably at N.M. Rothschild & Sons. Luke holds a BSc in Physiological Sciences from Newcastle University, UK.

Following this change, the Intrasense Board of Directors now consists of six members:

- [François Nicolas](#), Chairman of the Board
- [Charlotte Bamière](#), Director
- [Luke Poloniecki](#), Director
- [Anne Larpin](#), Independent Director
- [Patrice Rullier](#), Independent Director
- [Steven F. Tolle](#), Independent Director

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.

Intrasense Product portfolio includes Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, which optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers AI for the detection of pancreatic lesions, focal liver lesions, and the world's first CE-marked AI dedicated to bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AI, optimizes the longitudinal monitoring of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management.

More information on www.intrasense.fr

Contacts

INTRASENSE

Communication Officer

Salomé Sylvestre

Phone: +334 67 13 01 30

investisseurs@intrasense.fr

SEITOSEI.ACTIFIN

Investor relations

Foucauld Charavay

Phone: +336 37 83 33 19

intrasense@seitosei-actifin.com

Press relations

Isabelle Dray

Phone: +336 85 36 85 11

isabelle.dray@seitosei-actifin.com